A Study to Evaluate the Safety, Immunogenicity, and Pharmacokinetics of GR2303 in Healthy Adult

NCT07199270 · tracked via the Priya Life Science China tracker

Sponsor

Genrix (Shanghai) Biopharmaceutical Co., Ltd.

Phase

Phase 1

Started

2025-09-18

Last updated

2025-09-30

Condition(s) studied

Health Adult Subjects

Investigational drug(s) / intervention(s)

GR2303 injectionPlaceboGR2303 injectionPlacebo

GR2303 injection: single dose

Placebo: single dose

GR2303 injection: multiple dose

Placebo: multiple dose

Study summary

he goal this clinical trail is to evaluate the safety、Pharmacokinetic and immunogenicity of GR2303 injection。 Subjects will be enrolled in different groups in sequential order, and within each group will be randomly assigned to receive either GR2303 injection or placebo administration, with each Subjects will be enrolled in only one of these groups

Eligibility

Sex

ALL

Min age

18 Years

Max age

45 Years

Healthy volunteers

Accepted

Inclusion Criteria: 1. Healthy adult subjects 2. Signed informed consent Exclusion Criteria: 1. History or presence of any clinically significant organ system disease that could interfere with the objectives of the study or the safety of the subjects. 2. Prior use of drug targeting TNF-like cytokine 1A 3. history of malignant tumor 4. psitive results for Hepatitis B surface antigen (HBsAg), anti Hepatitis C antibody (HCV Ab) or human immunodeficiency virus (HIV)

Primary outcome measure(s)

Adverse events — 16 weeks

Trial sites (1)

Facility	City	Region	Status
Beijing Friendship hospital, Capital Medical University	Beijing	Beijing Municipality	Recruiting

More Genrix (Shanghai) Biopharmaceutical Co., Ltd. trials in China

Clinical Study to Investigate the Safety, Tolerability, and Pharmacokinetics of GR1603 in SLE Active, not recruiting

A Study of GR1803 Injection Versus Daratumumab, Pomalidomide, and Dexamethasone (DPd) in Participants With Relapsed or Refractory Multiple Myeloma Recruiting

A Study of GR1802 Injection in Patients With Seasonal Allergic Rhinitis. Starting soon

A Study of GR1803 in Systemic Lupus Erythematosus Recruiting

A Study of IL4Rα Monoclonal Antibody in Patients With Seasonal Allergic Rhinitis(SAR). Active, not recruiting

Other trials for the same condition

Pharmacokinetic Characteristics, Safety, and Immunogenicity of HLX29 Compared With HLX11 Starting soon

Study of HXN6005 in Healthy Participants and Patients With Moderate-to-Severe Atopic Dermatitis Starting soon

Effects of NR Supplementation on Metabolic Flexibility in Zone 2 Training Recruiting

An Early-stage Clinical Trial to Evaluate the Safety, Absorption, and Disposition of YR001 Ointment Following Topical Application on the Skin of Healthy Chinese Subjects Recruiting

A Phase I Study of HXN5003 in Healthy Participants and Patients With Moderate-to-Severe Atopic Dermatitis Starting soon

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07199270 on ClinicalTrials.gov ↗ ← All trials in China